Search results for: ""

Showing 41-50 of 454 results

News - 10 young students from the sopraceneri area receive Helsinn Advanced Synthesis SA 2013/2014 Educational Scholarships 03/10/2013 12:00am

Helsinn is pleased to announce that on Friday October 4th, in the presence of Biasca's Town Mayor, Mr. Jean- François Dominé and Director of the professional training Division, Department of education, culture and sport, Mr. Paolo Colombo, the young award-winning students received 10 Helsinn Advanced Synthesis SA educational scholarships value of CHF 55.000- for the academic ye...

News - Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrom 12/11/2013 12:00am

Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrome related to non-small cell lung cancer in top EU markets

News - Helsinn Birex Pharmaceuticals wins two prestigious awards for its outstanding health and safety performance 29/10/2013 12:00am

Helsinn Birex Pharmaceuticals' (HBP) commitment and excellence in health and safety over many years was once again acknowledged with two coveted awards at the 22nd Annual NAtional Irish Safety Organisation/Northern Ireland Safety Group (NISO/NISG) Safety Awards ceremony, which took place il Galaway on October 4th 2013.

News - Helsinn Group's representative office in China: official inauguration 03/12/2013 12:00am

Helsinn Group, the independent, privately - owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially in augurated in Beijing, PRC yesterday.

News - Helsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agoni st Anamorelin in Italy 18/12/2013 12:00am

Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (N cell lung cancer (NSCLC).

News - Presentato il rapporto di sostenibilità 2012 di Helsinn Advanced Synthesis SA, presente a Biasca da 30 anni 19/12/2013 12:00am

Il polo chimico del Gruppo Helsinn redige, prima organizzazione privata con sede nel Canton Ticino, il proprio rapporto secondo le strettissime ed innovative linee guida del Global Reporting Initiative (GRI) ‐ Riccardo Braglia: "Helsinn Advanced Synthesis SA è un "Good Corporate Citizen", un "Buon Cittadino" che vuole contribuire a far crescere la nostra regione e a sostenere i...

News - Swiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China New Single News 28/11/2014 12:00am

The educational scholarships of 5.000.-CHF each, sponsored by Helsinn Advanced Synthesis Biasca, were awarded to 11 students living in Canton Ticino who are attending professional or academic training in the chemical, pharmaceutical, biological, biochemical or in similar fields; the scholarships have therefore been given to those carrying out an internship or attending the Fede...

News - Data presented at the International Society of Paediatric Oncology (SIOP) Congress show Palonosetron is a valuable option for treating pediatric patie 28/10/2014 12:00am

The data presented at the SIOP congress in Toronto, 22-24 October, today, October 23rd derive from a large randomized trial.

News - FDA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) 13/10/2014 12:00am

FDA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)